Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1982 1
1984 1
1988 1
1990 1
1991 2
1996 1
1997 1
1998 2
2001 1
2002 1
2003 1
2006 2
2008 2
2009 6
2010 4
2011 3
2012 2
2013 5
2014 1
2015 5
2016 4
2017 10
2018 5
2019 10
2020 5
2021 7
2022 8
2023 8
2024 3
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial.
Hall PS, Swinson D, Cairns DA, Waters JS, Petty R, Allmark C, Ruddock S, Falk S, Wadsley J, Roy R, Tillett T, Nicoll J, Cummins S, Mano J, Grumett S, Stokes Z, Kamposioras KV, Chatterjee A, Garcia A, Waddell T, Guptal K, Maisey N, Khan M, Dent J, Lord S, Crossley A, Katona E, Marshall H, Grabsch HI, Velikova G, Ow PL, Handforth C, Howard H, Seymour MT; GO2 Trial Investigators. Hall PS, et al. JAMA Oncol. 2021 Jun 1;7(6):869-877. doi: 10.1001/jamaoncol.2021.0848. JAMA Oncol. 2021. PMID: 33983395 Free PMC article. Clinical Trial.
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
Schmid P, Abraham J, Chan S, Wheatley D, Brunt AM, Nemsadze G, Baird RD, Park YH, Hall PS, Perren T, Stein RC, Mangel L, Ferrero JM, Phillips M, Conibear J, Cortes J, Foxley A, de Bruin EC, McEwen R, Stetson D, Dougherty B, Sarker SJ, Prendergast A, McLaughlin-Callan M, Burgess M, Lawrence C, Cartwright H, Mousa K, Turner NC. Schmid P, et al. Among authors: hall ps. J Clin Oncol. 2020 Feb 10;38(5):423-433. doi: 10.1200/JCO.19.00368. Epub 2019 Dec 16. J Clin Oncol. 2020. PMID: 31841354 Free article. Clinical Trial.
Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial.
Dunn JA, Donnelly P, Elbeltagi N, Marshall A, Hopkins A, Thompson AM, Audisio R, Pinder SE, Cameron DA, Hartup S, Turner L, Young A, Higgins H, Watson EK, Gasson S, Barrett-Lee PJ, Hulme C, Shinkins B, Hall PS, Evans A. Dunn JA, et al. Among authors: hall ps. Lancet. 2025 Feb 1;405(10476):396-407. doi: 10.1016/S0140-6736(24)02715-6. Lancet. 2025. PMID: 39892911 Free article. Clinical Trial.
An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma.
Baxter MA, Spender LC, Cairns D, Walsh S, Oparka R, Porter RJ, Bray S, Skinner G, King S, Turbitt J, Collinson D, Miedzybrodzka ZH, Jellema G, Logan G, Kennedy RD, Turkington RC, McLean MH, Swinson D, Grabsch HI, Lord S, Seymour MJ, Hall PS, Petty RD. Baxter MA, et al. Among authors: hall ps. ESMO Open. 2024 May;9(5):103450. doi: 10.1016/j.esmoop.2024.103450. Epub 2024 May 13. ESMO Open. 2024. PMID: 38744099 Free PMC article. Clinical Trial.
Current perspective - trastuzumab.
Hall PS, Cameron DA. Hall PS, et al. Eur J Cancer. 2009 Jan;45(1):12-8. doi: 10.1016/j.ejca.2008.10.013. Epub 2008 Nov 29. Eur J Cancer. 2009. PMID: 19042123 Free article. Review.
103 results